In Brief: Pfizer's Feldene (piroxicam)
This article was originally published in The Tan Sheet
Executive Summary
Pfizer's Feldene (piroxicam): FDA's Arthritis Advisory Committee will meet Oct. 11 to consider safety and labeling issues presented in a December 1994 Public Citizen Health Research Group citizen petition requesting the removal from the market of drugs containing piroxicam because of a significantly higher risk of gastropathy compared to other nonsteroidal anti-inflammatory drugs (NSAIDs). On Oct. 12, the committee will examine the adequacy of gastropathy warnings in labeling for NSAIDs as a class. The Oct. 11 meeting will be at the Gaithersburg Holiday Inn starting at 8 a.m. and the Oct. 12 meeting at the Silver Spring Holiday Inn at 8:30 a.m...